Liver imaging

  • Liver Int. 2018.In press. Liver imaging. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Sciarra A, Schmidt S, Pellegrinelli A, Maggioni M, Dondossola D, Pasquier J, Cigala C, Tosi D, Halkic N, Bulfamante G, Viale G, Bosari S, Balabaud C, Bioulac-Sage P, Sempoux C. PubMed
  • AJR Am J Roentgenol. 2018;211:347-357. Liver imaging. Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of Gadoxetic Acid-enhanced MRI and focal nodular hyperplasia by CT and MRI. Kitao A, Matsui O, Yoneda N, Kita R, Kozaka K, Kobayashi S, Gabata T. PubMed
  • EJNMMI Res. 2018;8:81. Liver imaging. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.  Amor D, Goutal S, Marie S, Caillé F, Bauer M, Langer O, Auvity S, Tournier N. PubMed
  • Clin Pharmacol Ther. 2018;104,749-756. Liver imaging. Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate. Ali I, Slizgi JR, Kaullen JD, Ivanovic M, Niemi M, Stewart PW, Barritt AS, Brouwer KLR. PubMed

Uptake activity of transporters

  • Xenobiotica. 2018;21:1-11Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans. Liao M, Zhu Q, Zhu A, Gemski C, Ma B, Guan E, Li AP, Xiao G, Xia CQ. PubMed

OCT1 deficiency

  • Clin Pharmacol Ther. 2018; in press. OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of Cycloguanil, the active metabolite of the antimalarial drug Proguanil. Matthaei J, Seitz T, Jensen O, Tann A, Prukop T, Tadjerpisheh S, Brockmöller J, Tzvetkov MV. PubMed

Drug-drug interactions

  • Clin Ther. 2018;40:1322-1337 A comprehensive in vivo and in vitro assessment of the drug interaction potential of Red Ginseng. Seong SJ, Kang WY, Heo JK, Jo J, Choi WG, Liu KH, Lee S, Choi MK, Han YH, Lee HS, Ohk B, Lee HW, Song IS, Yoon YR. PubMed
  • Mol Pharm. 2018;15:3060-3068. In silico and in vitro assessment of OATP1B1 inhibition in drug discovery. Danielson ML, Sawada GA, Raub TJ, Desai PV. PubMed
  • Clin Pharmacol Ther. 2018;104:564-574. Gaining mechanistic insight into Coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation. Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. PubMed
  • Clin Pharmacol Ther. 2018; Model-based assessments of CYP-mediated drug-drug interaction risk of Alectinib: physiologically based pharmacokinetic modeling supported clinical development. Cleary Y, Gertz M, Morcos PN, Yu L, Youdim K, Phipps A, Fowler S, Parrott N. PubMed

Passive and transporter-mediated uptake clearance

  • Mol Pharm. 2018,15, 4677-4688. Assessment of transporter-mediated and passive hepatic uptake clearance using rifamycin-SV as a pan-inhibitor of active uptake. Chothe PP, Wu SP, Ye Z, Hariparsad N. PubMed
  • Drug Metab Dispos. 2018;In press. When does the rate-determining step in the hepatic clearance of a drug switch from sinusoidal uptake to all hepatobiliary clearances? Implications for predicting drug-drug interactions. Patilea-Vrana GI, Unadkat J. PubMed

Drug-metabolising enzymes

  • Clin Pharmacol Ther. 2018; Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Drozdzik M, Busch D, Lapczuk J, Müller J, Ostrowski M, Kurzawski M, Oswald S. PubMed

Liver toxicity

  • Clin Pharmacol Ther. 2018;104:458-469. Botanicals and hepatotoxicity. Roytman MM, Poerzgen P, Navarro V. PubMed

Plasma bile acid concentrations and transporters

  • Liver Int. 2018;38:1676-1685. Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations. Liu T, Wang RX, Han J, Hao CZ, Qiu YL, Yan YY, Li LT, Wang NL, Gong JY, Lu Y, Zhang MH, Xie XB, Yang JC, You YJ, Li JQ, Knisely AS, Borchers CH, Ling V, Wang JS. PubMed
  • J Appl Toxicol. 2018;38:1323-1335. Species differences in bile acids I. Plasma and urine bile acid composition. Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y. PubMed
  • J Appl Toxicol. 2018;38:1336-1352.Species differences in bile acids II. Bile acid metabolism. Thakare R, Alamoudi JA, Gautam N, Rodrigues AD, Alnouti Y. PubMed
  • Hepatology. 2018; 68:1057-1069. Na+-taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. PubMed
  • Am J Physiol Gastrointest Liver Physiol. 2018;315:G511-G513. A luminescent future for the study of bile acid transporters. Wu N, Alpini G. PubMed